方盛制药(603998.SH)：公司研发的吲哚布芬片已获得药品批准文号

Core Viewpoint - The approval of Indobufen tablets by the National Medical Products Administration enhances the company's product line in cardiovascular medications and strengthens its market competitiveness [1][2]. Company Summary - The company has received the drug registration certificate for Indobufen tablets, which is a platelet aggregation inhibitor used primarily for ischemic cardiovascular and cerebrovascular diseases, as well as for preventing thrombosis during hemodialysis [1]. - The approval of Indobufen tablets enriches the company's existing portfolio of cardiovascular drugs, which includes products like Ezetimibe tablets, Irbesartan Hydrochlorothiazide tablets, and others [2]. - The company’s cardiovascular drugs have already captured a certain market share, and the new approval is expected to improve overall profitability [2]. Industry Summary - The demand for cardiovascular medications has created a substantial market, leading to significant opportunities for companies in this sector [2]. - The approval of Indobufen tablets does not require further consistency evaluation, aligning with the regulations set forth in the relevant government document [2].